Copertina

Letter: Interpreting Apparent P‐ CAB Superiority for Antithrombotic‐Associated Upper Gastrointestinal Bleeding

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Xiaoqing Yang, Guihua Zhao
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

P‐ CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study
di: Min Joo Yoon, et al.
Pubblicazione: (2026)

Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
di: Jiaqi Shen, et al.
Pubblicazione: (2026)

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial
di: Yu Yang, et al.
Pubblicazione: (2024)

Antiplatelet Resumption Timing in Post‐Percutaneous Coronary Intervention Gastrointestinal Bleeding
di: Darrick K. Li, et al.
Pubblicazione: (2026)

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial. Authors' Reply
di: Nauzer Forbes, et al.
Pubblicazione: (2024)

Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs
di: Ali S. Taha
Pubblicazione: (2026)

Research Communication: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
di: Lauren Holtslander, et al.
Pubblicazione: (2025)

Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs . Authors' Reply
di: Min Joo Yoon, et al.
Pubblicazione: (2026)

Letter: Post‐Banding Ulcer Bleeding Is More Common With Urgent EBL and Renal Dysfunction
di: Jurij Maurer, et al.
Pubblicazione: (2026)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
di: Hassan Javed, et al.
Pubblicazione: (2025)

Letter on ‘Clinical Trial: Effect of a 28‐Day Low FODMAP Diet on Gastrointestinal Symptoms Associated With Endometriosis ( EndoFOD )—A Randomised, Controlled Crossover Feeding Study’
di: Wancheng Zhao, et al.
Pubblicazione: (2025)

Letter: Interpreting Faecal SCFA Enrichment in IBS‐D—Metabolic Signal or Transit‐Related Marker?
di: Longying Zhang, et al.
Pubblicazione: (2026)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
di: Leyu Zhou, et al.
Pubblicazione: (2024)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma
di: Sifu Yang
Pubblicazione: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol‐Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment
di: Shupeng Zhao, et al.
Pubblicazione: (2025)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
di: Hong‐Li Liu, et al.
Pubblicazione: (2026)

Letter on ‘Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicentre Real‐World’
di: Silvia Nardelli, et al.
Pubblicazione: (2025)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis
di: Ao Gao, et al.
Pubblicazione: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
di: Zhejin Shi, et al.
Pubblicazione: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
di: Jiwon Yang, et al.
Pubblicazione: (2025)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
di: Chachrit Khunsriraksakul, et al.
Pubblicazione: (2025)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
di: Chen‐Pi Li, et al.
Pubblicazione: (2024)

Letter: Association between terlipressin and multi‐drug‐resistant organism rectal colonisation
di: Katrina Tan, et al.
Pubblicazione: (2024)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
di: Dingsheng Liu, et al.
Pubblicazione: (2025)

Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI
di: Benjamin Douglas Liu, et al.
Pubblicazione: (2025)

Letter: Beyond Survival Benefit in CHANCE2311—Important Considerations in the Interpretation of TACE Combined With Immunotherapy in Advanced HCC
di: Yinghan Chen, et al.
Pubblicazione: (2026)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate
di: Wen‐Juei Jeng, et al.
Pubblicazione: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
di: Cong Dai, et al.
Pubblicazione: (2024)

Letter: Meta‐Analysis Critique: Refining the Association Between Helicobacter pylori and Eosinophilic Oesophagitis
di: Haleema Rahman
Pubblicazione: (2025)

Letter: Association between terlipressin and multidrug‐resistant organism rectal colonization: Authors' reply
di: Marcus M. Mücke, et al.
Pubblicazione: (2024)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
di: Stergios A. Polyzos, et al.
Pubblicazione: (2024)

Editorial: Gastrointestinal symptoms—A world of differences
di: Kevin W. Olden
Pubblicazione: (2024)

Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance
di: Hsiang‐Ting Keng, et al.
Pubblicazione: (2026)

Letter on ‘Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma’
di: Dong Hyun Kim, et al.
Pubblicazione: (2025)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
di: Jiamei Wang, et al.
Pubblicazione: (2024)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
di: Kanghee Park, et al.
Pubblicazione: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
di: Jeffrey D. McCurdy, et al.
Pubblicazione: (2025)